Schroder Investment Management Group
CCCC icon

Schroder Investment Management Group’s C4 Therapeutics CCCC Stock Holding History

Schroder Investment Management Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-405,885
Closed -$1.88M – 1207
2024
Q2 		$1.88M Buy
+405,885
New +$2.42M ﹤0.01% 937

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Schroder Investment Management Group's CCCC Position: Q3 2024 in Review

Schroder Investment Management Group sold out of C4 Therapeutics (CCCC) in Q3 2024, closing a stake of 405,885 shares — an estimated $1.88M sold.

Schroder Investment Management Group first reported a position in CCCC in Q2 2024 and held it in 1 quarter. The position peaked at $1.88M in Q2 2024. 118 funds tracked by Wall St. Rank hold CCCC as of Q3 2024.

  • Schroder Investment Management Group reported no remaining C4 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Schroder Investment Management Group sold 405,885 C4 Therapeutics shares in Q3 2024, an estimated $1.88M.
  • Schroder Investment Management Group first reported a position in C4 Therapeutics in Q2 2024 and held it in 1 quarter.
  • Schroder Investment Management Group's C4 Therapeutics position peaked at $1.88M in Q2 2024.
  • 118 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2024.

Based on Schroder Investment Management Group's 13F filing for Q3 2024, filed 13 Nov 2024.